Inhibikase Therapeutics Completes Enrollment Of Its Phase 2 '201' Trial Of Risvodetinib In Untreated Parkinson's Disease
Portfolio Pulse from Benzinga Newsdesk
Inhibikase Therapeutics has completed enrollment for its Phase 2 '201' trial of Risvodetinib, targeting untreated Parkinson's disease.
June 17, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibikase Therapeutics has completed enrollment for its Phase 2 '201' trial of Risvodetinib, which targets untreated Parkinson's disease. This milestone could positively impact the company's stock as it progresses in its clinical trials.
Completing enrollment for a Phase 2 trial is a significant milestone in drug development. It indicates progress and potential future success, which can boost investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100